Group 1 - The company reported a revenue of RMB 639 million for the six months ending June 30, 2025, representing a year-on-year decline of 9.05% [1] - Gross profit was RMB 525 million, down 2.84% year-on-year, while net profit attributable to shareholders was RMB 90.17 million, a decrease of 14.4% [1] - The decline in revenue was attributed to both internal and external factors, including intensified national healthcare cost control measures and adjustments in drug pricing policies [1] Group 2 - The company experienced over 10% year-on-year growth in sales of orthopedic products, with an increasing hospital penetration rate [2] - The company aims for stable revenue growth by implementing differentiated commercial policies and enhancing professional academic promotion in the orthopedic market [2] - The company is focused on expanding its research and development pipeline in the fields of metabolism, orthopedics, oncology, and hematology, including multiple innovative drugs and biosimilars [2]